We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 26,328

Can you file an RCE in that U.S. national stage application?
  • Foley & Lardner LLP
  • USA
  • July 28 2015

Since the implementation of the America Invents Act on September 16, 2012, and the Technical Corrections Act on January 14, 2013, Applicants have


Pharmaceutical follow-on patents - maintaining market exclusivity in the pharmaceutical industry
  • FB Rice
  • Australia
  • July 28 2015

Often, a pharmaceutical does not earn revenue for a company until well into the patent term; sometimes this may be 15 years or more into the term


Pharma in brief - Federal Court of Appeal finds that “promised” utility need not be coterminous with the inventive concept
  • Norton Rose Fulbright Canada LLP
  • Canada
  • July 27 2015

AstraZeneca Canada Inc. (AstraZeneca) appealed from the decision of Justice Rennie of the Federal Court (reported as AstraZeneca Canada Inc. v


The 2014 IP case that renders GUI design patentable in China
  • Tsai Lee & Chen Patent Attorneys & Attorneys at Law
  • China
  • July 27 2015

On April 20th 2015 in Chong Qing at a National Judicial Courts IPR Protection Event, China’s Supreme People’s Court announced the top 10 innovative


Taiwan and Korea sign Memoranda of Understanding for patent cooperation
  • Tsai Lee & Chen Patent Attorneys & Attorneys at Law
  • South Korea, Taiwan
  • July 27 2015

Taiwan and Korea signed a Memorandum of Understanding for the Patent Prosecution Highway Program (the PPH Program) on June 15, 2015


The European Court of Justice on enforcement of FRAND patents: Huawei v. ZTE
  • Morrison & Foerster LLP
  • European Union
  • July 27 2015

The European Court of Justice (ECJ) rendered its highly anticipated ruling in Huawei v. ZTE on the enforcement of standard essential patents (SEPs


ECJ rips up Orange Book! New standards in Europe for SEP injunctions
  • White & Case LLP
  • European Union
  • July 27 2015

Standards lie at the heart of the Digital Economy without standards, we would not have smartphones, tablets and other key parts of modern life


Kaneka v. Xiamen Kingdomway Group: implicit order read into method steps of industrial biotechnology patent
  • Sterne Kessler Goldstein & Fox
  • USA
  • July 27 2015

The Federal Circuit's recent decision in Kaneka Corp. v. Xiamen Kingdomway Group Co. (Fed. Cir. 2015) serves as a reminder that courts may implicitly


“A riddle wrapped in a mystery inside an enigma”: the Federal Circuit attempts to decode the BPCIA
  • Finnegan, Henderson, Farabow, Garrett & Dunner LLP
  • USA
  • July 27 2015

On July 21, 2015, the Federal Circuit issued a divided decision in Amgen Inc. v. Sandoz Inc., No. 15-1499 (Fed. Cir. July 21, 2015), interpreting two


Judicial review available for decision that a patent qualified for CBM review; 101 review appropriate in CBM review
  • Fish & Richardson PC
  • USA
  • July 27 2015

Federal Circuit affirms determination, following CBM (“covered business method”) review, of invalidity under 101, and resolves several procedural